Hot Blue Chip Stocks To Buy Right Now

The stock market gave up ground on Tuesday, but investors saw major benchmarks recover from their worst levels of the day to finish down less than half a percent. Early in the day, poor earnings results from blue chip components of the Dow Jones Industrials weighed on market sentiment, and ongoing uncertainty about whether the Trump administration will be able to deliver on promised government reforms made some investors feel less confident about the future. However, several companies reported good news despite the dour mood on Wall Street, and GNC Holdings (NYSE:GNC), Stratasys (NASDAQ:SSYS), and Cabela’s (NYSE:CAB) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

GNC eases shareholders’ concerns

Shares of GNC Holdings jumped 24% after the company posted first-quarter results that, while not perfect, were still not as bad as some investors had feared. Revenue fell 4% from year-ago levels, and same-store sales dropped 3.9% in company-owned locations and 4.6% in domestic franchise stores. Moreover, net income dropped by more than half, leaving the company with just $0.37 per share in adjusted earnings. Yet those numbers encouraged those who are patient enough to give GNC time to remake itself, and CEO Bob Moran pointed to the company’s One New GNC transformation strategy as having shown signs of early success. With new loyalty programs producing some positive effects on transaction counts and volume, GNC hopes that business metrics will hit bottom and start to grow again in the near future.

Hot Blue Chip Stocks To Buy Right Now: InnerWorkings, Inc.(INWK)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Shares of InnerWorkings, Inc. (NASDAQ:INWK) have been assigned an average recommendation of “Hold” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $14.00.

  • [By Garrett Baldwin]

    Shares of Ford Motor Co.(NYSE: F) were flat despite dismal news out of China. This morning, the company reported a 38% slump in Chinese sales during the month of June. It was a terrible first six months for the iconic vehicle manufacturer. The company said that its Chinese operations saw a 25% slide in sales over the first half of the year. That was the largest six-month decline since launching its Chinese operations in 2001. Shares of Tesla Inc. (Nasdaq: TSLA) are off more than 1% after California regulators announced a new probe into the company. The probe was announced following a safety complaint filed with the Occupational Safety and Health Administration. The agency has not provided any details on the case. Shares of Biogen Inc. (Nasdaq: BIIB) popped more than 14% after the company announced positive results from a trial for an Alzheimer’s drug. The phase 2 study examined BAN2401, an anti-amyloid beta protofibril antibody. It was tested on 856 patients with early stages of Alzheimer’s disease. In a research note, JPMorgan Chase & Co. (NYSE: JPM) announced that the results would be positive for Biogen’s drug pipeline. Look for an earnings report Friday from InnerWorkings Inc. (Nasdaq: INWK). Wall Street projects that the company will report earnings per share of $0.09 on top of $284.9 million in revenue.

    Follow Money MorningonFacebook, Twitter, and LinkedIn.

  • [By Ethan Ryder]

    Total System Services (NYSE: TSS) and InnerWorkings (NASDAQ:INWK) are both business services companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Hot Blue Chip Stocks To Buy Right Now: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Jason Hall, George Budwell, and Chuck Saletta]

    In order to help you get started, we asked three real-world investors who also write for The Motley Fool to put forth their best “buy now” growth stock ideas, and they came up with high-growth home builderLGI Homes Inc(NASDAQ:LGIH),return-to-growth restaurant chainChipotle Mexican Grill, Inc.(NYSE:CMG), and upstart immunotherapy developerAtara BioTherapeutics Inc(NASDAQ:ATRA).

  • [By Joseph Griffin]

    Atara Biotherapeutics (NASDAQ:ATRA) had its price target decreased by Citigroup from $25.00 to $23.00 in a report released on Monday. Citigroup currently has a sell rating on the biotechnology company’s stock.

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

  • [By Joseph Griffin]

    Atara Biotherapeutics (NASDAQ:ATRA) Director Matthew K. Fust sold 12,286 shares of Atara Biotherapeutics stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $43.57, for a total value of $535,301.02. Following the completion of the transaction, the director now directly owns 19,820 shares of the company’s stock, valued at approximately $863,557.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

  • [By Joseph Griffin]

    Rhumbline Advisers boosted its position in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 23.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 33,565 shares of the biotechnology company’s stock after purchasing an additional 6,363 shares during the quarter. Rhumbline Advisers’ holdings in Atara Biotherapeutics were worth $1,309,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Atara Biotherapeutics (NASDAQ:ATRA) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.13), MarketWatch Earnings reports.

Hot Blue Chip Stocks To Buy Right Now: Antares Pharma, Inc.(ATRS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Antares Pharma (ATRS)

    For more information about research offerings from Zacks Investment Research, visit

  • [By Logan Wallace]

    BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning.

  • [By Stephan Byrd]

    Antares Pharma, Inc. (NASDAQ:ATRS) Director Jacques Gonella sold 300,000 shares of the firm’s stock in a transaction dated Wednesday, May 9th. The stock was sold at an average price of $2.47, for a total value of $741,000.00. Following the completion of the sale, the director now directly owns 11,936,413 shares of the company’s stock, valued at approximately $29,482,940.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Leave a Reply

Your email address will not be published. Required fields are marked *